Core Viewpoint - The pharmaceutical industry is experiencing a significant divide, with some representatives thriving while others face severe challenges due to policy changes and market dynamics [3][8]. Group 1: Industry Challenges - The introduction of centralized procurement and anti-corruption measures has drastically reduced profit margins for pharmaceutical companies, leading to a stark contrast in the experiences of industry representatives [4][17]. - In 2024, nearly half of listed pharmaceutical companies are expected to report rising performance, while the other half will see declines, indicating a bifurcation in the industry [8][19]. - The marketing expense ratios of pharmaceutical companies have significantly decreased, with some companies experiencing reductions of over 70% from 2019 to 2024 [20]. Group 2: Impact of Centralized Procurement - Centralized procurement has led to drastic price reductions for drugs, with some products seeing profit margins drop from 1000% to just 10% overnight [22][25]. - The frequency of centralized procurement announcements has increased, affecting a wide range of drugs and medical devices, leading to widespread layoffs among pharmaceutical representatives [23][26]. - Major pharmaceutical companies have significantly reduced their sales teams, with some companies cutting their workforce by over 50% since 2020 [26]. Group 3: Changing Dynamics for Representatives - The role of pharmaceutical representatives is evolving, with a greater emphasis on professionalism and knowledge as traditional sales tactics become less effective [32][34]. - Despite the challenges, some representatives still see potential in the industry, citing opportunities in online sales and the growing acceptance of e-commerce for pharmaceuticals [36][38]. - The industry remains a relatively high-income sector compared to other traditional industries, with starting salaries for representatives still competitive [34].